In a retrospective case series of 15 veterans with treatment‑resistant depression and comorbid PTSD who switched from intranasal (S)‑ketamine to intravenous racemic (R,S)‑ketamine, IV treatment was associated with larger and statistically significant reductions in PHQ‑9 and PCL‑5 scores while reductions after IN (S)‑ketamine were smaller and not significant. The authors suggest IV racemic ketamine may be a reasonable next step for inadequate responders to IN (S)‑ketamine, but randomised, double‑blind trials are needed.
- Published
- Journal
- Pharmacotherapy
- Authors
- Bentley, S., Artin, H., Mehaffey, E., Liu, F., Sojourner, K., Bismark, |. A., David Printz, |., Lee, E. E., Martis, B., De Peralta, S., Baker, D. G., Mishra, J., Ramanathan, D.